TSCA Chemical Testing; Receipt of Test Data, 1538-1540 [E6-100]

Download as PDF 1538 Federal Register / Vol. 71, No. 6 / Tuesday, January 10, 2006 / Notices For Losses: Capacity and energy losses incurred in connection with the transmission and delivery of capacity and energy under this rate schedule shall be supplied by the customer in accordance with the contract or service agreement. Rate Schedule CAP–NITS2 Supersedes Rate Schedule CAP–NITS1 United States Department of Energy Western Area Power Administration Central Arizona Project Schedule of Rate(s) for Network Integration Transmission Service Effective: The first day of the first full billing period beginning on or after January 1, 2006, through December 31, 2010. Applicable: The transmission customer shall compensate the CAP each month for Network Integration Transmission Service (NITS) pursuant to the applicable Network Integration Transmission Service Agreement and annual revenue requirement referred to below. The formula for the annual revenue requirement used to calculate the charges for this service under this schedule was promulgated and may be modified pursuant to applicable Federal laws, regulations, and policies. The Desert Southwest Region (DSW) may modify the charges for NITS upon written notice to the transmission customer. DSW shall charge the transmission customer in accordance with the revenue requirement then in effect. Formula Rate Monthly Charge = Transmission Customer’s Load-Ratio Share × (Revenue Requirement/12) Calculated Rate The NITS rate is calculated using a projected annual revenue requirement. Based on updated financial and load data, a recalculated revenue requirement will go into effect on January 1 of each year during the effective rate schedule period. [FR Doc. E6–110 Filed 1–9–06; 8:45 am] BILLING CODE 6450–01–P ENVIRONMENTAL PROTECTION AGENCY [FRL–8020–5] National Advisory Council for Environmental Policy and Technology Environmental Technology Subcommittee Environmental Protection Agency (EPA). ACTION: Notice of meeting. wwhite on PROD1PC65 with NOTICES AGENCY: SUMMARY: Under the Federal Advisory Committee Act, Public Law 92463, EPA gives notice of a meeting of the Environmental Technology Subcommittee of the National Advisory Council for Environmental Policy and Technology (NACEPT). NACEPT VerDate Aug<31>2005 16:09 Jan 09, 2006 Jkt 208001 provides advice and recommendations to the Administrator of EPA on a broad range of environmental policy, technology, and management issues. The Environmental Technology Subcommittee was formed to assist EPA in evaluating its current and potential role in the development and commercialization of environmental technologies by suggesting how to optimize existing EPA programs to facilitate the development of sustainable private sector technologies, and by suggesting alternative approaches to achieving these goals. The purpose of the meeting is to discuss the Subcommittee’s recommendations on these issues. The Subcommittee will also discuss new issues that it may address in the future. A copy of the agenda for the meeting will be posted at https://www.epa.gov/ocem/nacept/calnacept.htm. DATES: The NACEPT Environmental Technology Subcommittee will hold a two day open meeting on Thursday, January 19, from 9 a.m. to 5 p.m. and Friday, January 20, from 8:30 a.m. to 1:30 p.m. Due to extenuating circumstances, contractual arrangements of the meeting space were delayed. ADDRESSES: The meeting will be held at the Madison Hotel, 1177 15th Street, NW., Washington, DC 20005. The meeting is open to the public, with limited seating on a first-come, firstserved basis. FOR FURTHER INFORMATION CONTACT: Mark Joyce, Designated Federal Officer, joyce.mark@epa.gov, 202–233–0068, U.S. EPA, Office of Cooperative Environmental Management (1601E), 1200 Pennsylvania Avenue, NW., Washington, DC 20460. SUPPLEMENTARY INFORMATION: Requests to make oral comments or provide written comments to the Subcommittee should be sent to Mark Joyce, Designated Federal Officer, at the contact information above. The public is welcome to attend all portions of the meeting. Meeting Access: For information on access or services for individuals with disabilities, please contact Mark Joyce at 202–233–0068 or joyce.mark@epa.gov. To request accommodation of a disability, please contact Mark Joyce, preferably at least 10 days prior to the meeting, to give EPA as much time as possible to process your request. Dated: January 4, 2006. Sonia Altieri, Designated Federal Officer. [FR Doc. E6–98 Filed 1–9–06; 8:45 am] BILLING CODE 6560–50–P PO 00000 Frm 00033 Fmt 4703 Sfmt 4703 ENVIRONMENTAL PROTECTION AGENCY [EPA–HQ–OPPT–2003–0006; FRL–7746–6] TSCA Chemical Testing; Receipt of Test Data Environmental Protection Agency (EPA). ACTION: Notice. AGENCY: SUMMARY: This notice announces EPA’s receipt of test data regarding In Vitro Dermal Absorption Rate Testing of Certain Chemicals of Interest to the Occupational Safety and Health Administration. Data were received on the following chemicals: Biphenyl (CAS No. 92-52-4); tert-butylcatechol (TBC) (CAS No. 98-29-3); carbon disulfide (CAS No. 75-15-0); catechol (CAS No. 120-80-9); chlorobenzene (CAS No. 10890-7); cyclohexanol (CAS No. 108-93-0); p-dichlorobenzene (CAS No. 106-46-7); dimethylacetamide (DMAc) (CAS No. 127-19-5); ethylene dichloride (CAS No. 107-06-2); hydroquinone monomethyl ether (HQMME) (CAS No. 150-76-5); methyl formate (CAS No. 107-31-3); vinyl toluene (CAS No. 25013-15-4); and p-xylene (CAS No. 106-42-3). These data were submitted pursuant to a test rule issued by EPA under section 4 of the Toxic Substances Control Act (TSCA). FOR FURTHER INFORMATION CONTACT: Colby Lintner, Regulatory Coordinator, Environmental Assistance Division (7408M), Office of Pollution Prevention and Toxics, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460–0001; telephone number: (202) 554–1404; e-mail address: TSCA-Hotline@epa.gov. SUPPLEMENTARY INFORMATION: I. General Information A. Does this Action Apply to Me? This action is directed to the public in general. This action may, however, be of interest to those persons who are concerned about data on health and/or environmental effects and other characteristics of this chemical. Since other entities may also be interested, the Agency has not attempted to describe all the specific entities that may be affected by this action. If you have any questions regarding the applicability of this action to a particular entity, consult the person listed under FOR FURTHER INFORMATION CONTACT. B. How Can I Get Copies of this Document and Other Related Information? 1. Docket. EPA has established an official public docket for this action under docket identification (ID) number E:\FR\FM\10JAN1.SGM 10JAN1 Federal Register / Vol. 71, No. 6 / Tuesday, January 10, 2006 / Notices wwhite on PROD1PC65 with NOTICES EPA–HQ–OPPT–2003–0006. The official public docket consists of the documents specifically referenced in this action, any public comments received, and other information related to this action. Although a part of the official docket, the public docket does not include Confidential Business Information (CBI) or other information whose disclosure is restricted by statute. The official public docket is the collection of materials that is available for public viewing at the EPA Docket Center, Rm. B102-Reading Room, EPA West, 1301 Constitution Ave., NW., Washington, DC. The EPA DocketCenter is open from 8:30 a.m. to 4:30 p.m., Monday through Friday, excluding legal holidays. The EPA Docket Center Reading Room telephone number is (202) 566–1744 and the telephone number for the OPPT Docket, which is located in EPA Docket Center, is (202) 566–0280. 2. Electronic access. You may access this Federal Register document electronically through the EPA Internet under the ‘‘Federal Register’’ listings at https://www.epa.gov/fedrgstr/. Agency Website: EPADOCKET, EPA’s electronic public docket and comment system was replaced on November 25, 2005, by an enhanced federal-wide electronic docket management and comment system located at https:// www.regulations.gov/. Follow the online instructions. An electronic version of the public docket is available through EPA’s electronic public docket and comment system, EPA Dockets. You may use EPA Dockets at https://www.epa.gov/edocket/ to submit or view public comments, access the index listing of the contents of the official public docket, and to access those documents in the public docket that are available electronically. Although not all docket materials may be available electronically, you may still access any of the publicly available docket materials through the docket facility identified in Unit I.B.1. Once in the system, select ‘‘search,’’ then key in the appropriate docket ID number. II. Test Data Submissions Section 4(d) of TSCA requires EPA to publish a notice in the Federal Register reporting the receipt of test data submitted pursuant to test rules promulgated under section 4(a) within 15 days after these data are received by EPA. 1. Test data for biphenyl were submitted by the Biphenyl Work Group and received by EPA on June 17, 2005. The submission includes a final study report submission titled: ‘‘In Vitro Dermal Absorption Rate Testing.’’ (See VerDate Aug<31>2005 16:09 Jan 09, 2006 Jkt 208001 document ID No. EPA–HQ–2003–0006– 0273.) The submission also includes a letter clarifying that the Biphenyl Work Group is not claiming trade secrecy or confidentiality on this report. 2. Test data for TBC were submitted by the Tertiary-Butylcatechol Consortium and received by EPA on July 20, 2005. The submission includes a final report titled: ‘‘[14C] TertButylcatechol (TBC): Percutaneous Penetration of [14C] Tert-Butylcatechol Through Human Split-thickness Skin Membranes (in-vitro).’’ (See document ID No. EPA–HQ–2003–0006–0284.) 3. Test data for carbon disulfide were submitted by the Carbon Disulfide Dermal Absorption Task Group (Task Group) of the American Chemistry Council and received by EPA on August 15, 2005. The submission includes an appended final study report titled: ‘‘Carbon Disulfide: In Vitro Dermal Absorption Rate Testing.’’ (See document ID No. EPA–HQ–2003–0006– 0289.) 4. Test data on catechol were submitted by the Catechol Consortium and received by EPA on August 26, 2005. The submission includes a final study report titled ‘‘[14C] Catechol: Percutaneous Penetration of [14C] Catechol Through Human Splitthickness Skin Membranes (in-vitro).’’ (See document ID No. EPA–HQ–2003– 0006–0287.) 5. Test data for chlorobenzene were submitted by the Chlorobenzene Producers Association (CPA) and received by EPA on June 6, 2005. The submission includes a final study report titled ‘‘Chlorobenzene: In Vitro Dermal Absorption Rate Testing.’’ (See document ID No. EPA–HQ–2003–0006– 0255.) 6. Test data for cyclohexanol were submitted on behalf of the Cyclohexanol Dermal Absorption Testing Committee and received by EPA on August 29, 2005. The submission includes a final study report from SafePharm Laboratories titled: ‘‘The In Vitro Dermal Absorption of [14C] Cyclohexanol through Human Skin.’’ (See document ID No. EPA–HQ–2003– 0006–0286.) 7. Test data for p-dichlorobenzene were submitted by the Chlorobenzene Producers Association and received by EPA on June 6, 2005. The submission includes a final study report titled: ‘‘pDichlorobenzene: In Vitro Dermal Absorption Rate Testing.’’ (See document ID No. EPA–HQ–2003–0006– 0255.) 8. Test data for DMAc were submitted by DuPont Chemical Solutions Enterprise and received by EPA on June 21, 2005. The submission includes a PO 00000 Frm 00034 Fmt 4703 Sfmt 4703 1539 final study report titled: ‘‘Dimethylacetamide: In Vitro Dermal Absorption Rate Testing.’’ (See document ID No. EPA–HQ–2003–0006– 0274.) 9. Test data for ethylene dichloride were submitted by the Hazardous Air Pollutant (HAP) Task Force and received by EPA on June 24, 2005. The submission includes a final study report titled: ‘‘Ethylene Dichloride: In Vitro Dermal Absorption Rate Testing.’’ (See document ID No. EPA–HQ–2003–0006– 0280.) 10. Test data for HQMME were submitted by the Hydroquinone Monomethyl Ether Dermal Absorption Task Group (Task Group) of the American Chemistry Council Hydroquinone Precursors and Derivatives Panel, and received by EPA on September 27, 2005. The submission includes an appended final study report titled: ‘‘Hydroquinone Monomethyl Ether: Measurement of the In Vitro Rate of Percutaneous Absorption Through Human Skin.’’ (See document ID No. EPA–HQ–2003–0006–0293.) 11. Test data for methyl formate were submitted by Celanese Chemicals and received by EPA on July 18, 2005. The submission includes a final study report titled: ‘‘Methyl Formate: In Vitro Dermal Absorption Rate Testing.’’ (See document ID Nos. EPA–HQ–2003– 0006–0281 and EPA–HQ–2003–0006– 0282.) The submission also includes a letter clarifying that Celanese is not claiming confidentiality on this report. 12. Test data for vinyl toluene were submitted on behalf of Deltech Corporation by the University of Louisiana and received by EPA on April 4, 2005. The submission includes a final study report submission titled: ‘‘Vinyl Toluene: In Vitro Dermal Absorption Rate Testing.’’ (See document ID Nos. EPA–HQ–2003–0006–0247 and EPA– HQ–2003–0006–0248.) The submission also includes two letters clarifying that the study is not claimed confidential or trade secret. 13. Test data for p-xylene were submitted by the p-Xylene Dermal Absorption Task Group of the American Chemistry Council and received by EPA on September 27, 2005. The submission includes an appended final study report titled: ‘‘p-Xylene: In Vitro Dermal Absorption Rate Testing.’’ (See document ID No. EPA–HQ–2003–0006– 0291.) These chemical substances are used in a wide variety of applications as industrial solvents, which may result in exposures of a substantial number of workers as described in the support document for the Proposed Rule (64 FR E:\FR\FM\10JAN1.SGM 10JAN1 1540 Federal Register / Vol. 71, No. 6 / Tuesday, January 10, 2006 / Notices 31074, June 9, 1999, Table 3 - Exposure Information for Chemical Substances). EPA has initiated its review and evaluation process for these submissions. At this time, the Agency is unable to provide any determination as to the completeness of the submissions. Authority: 15 U.S.C. 2603. List of Subjects Environmental protection, Hazardous substances. Dated: December 29, 2005. Jim Willis, Director, Chemical Control Division, Office of Pollution Prevention and Toxics. [FR Doc. E6–100 Filed 1–9–06; 8:45 am] BILLING CODE 6560–50–S Trans No. FEDERAL TRADE COMMISSION Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules Section 7A of the Clayton Act, 15 U.S.C. 18a, as added by Title II of the Hart-Scott-Rodine Antitrust Improvements Act of 1976, requires persons contemplating certain mergers or acquisitions to give the Federal Trade Commission and the Assistant Attorney General advance notice and to wait designated periods before consummation of such plans. Section 7A(b)(2) of the Act permits the agencies, in individual cases, to terminate this waiting period prior to its expiration Acquiring and requires that notice of this action be published in the Federal Register. The following transactions were granted early termination of the waiting period provided by law and the premerger notification rules. The grants were made by the Federal Trade Commission and the Assistant Attorney General for the Antitrust Division of the Department of Justice. Neither agency intends to take any action with respect to these proposed acquisitions during the applicable waiting period. Acquired Entities Transactions Granted Early Termination—12/05/2005 20060211 20060214 20060220 20060224 20060229 ......................... ......................... ......................... ......................... ......................... Chiron Corporation ............................ Preferred Care, Inc ............................ Joe Van Matre ................................... Spring Global S.A. ............................. Vestar-AIV Holdings A L.P. ............... Chiron Corporation. Preferred Care, Inc. Specialty Rental Tools Inc. Springs Global S.A. FL Spring, S.p.A. 20060235 ......................... Novartis AG ....................................... MVP Health Plan, Inc ........................ Allis-Chalmers Energy Inc ................. Josue Christiano Gomes da Silva ..... KKR European Fund II, Limited Partnership. Roger S. Penske ............................... Stephen P. Cushman ........................ 20060237 ......................... 20060240 ......................... Hanson PLC ...................................... Horizon Health Corporation ............... PaverModule, Inc. ............................. P. Byron DeFoor ............................... 20060241 ......................... 20060242 ......................... Ronald B. Dana ................................. Francisco Partners, L.P. .................... Rex V. Ecoff ...................................... FrontRange Limited ........................... 20060259 ......................... 20060264 ......................... 20060267 ......................... Lodge Holdco I LLC .......................... Berkshire Fund VI, L.P. ..................... GUS plc ............................................. La Quinta Corporation ....................... PDS Associates, Inc. ......................... PriceGrabber.com, LLC ..................... Cush A-KM, Inc., Cush Enterprises, Cush H-E, Inc., Cush J-KM, Inc., Cush M-E, Inc., M.S.M. Group, Inc. PaverModule, Inc. Delaware Investment Associates, LLC, Focus Healthcare, LLC, Focus Healthcare of Delaware, LLC, Focus Health of Florida, LLC, Focus Healthcare of Georgia, LLC, Focus Healthcare of Ohio, LLC, Highpoint Investment, LLC. Liquid Transport Corp. Cayo Communications, Inc., FrontRange Solutions Inc. La Quinta Corporation. PDS Associates, Inc. PriceGrabber.com, LLC. Transactions Granted Early Termination—12/06/2005 20060215 ......................... 20060275 ......................... Aleris International, Inc. ..................... Jones Lang LaSalle Incorporation .... Ormet Corporation ............................. Spaulding and Slye Partner LLC ...... Ormet Corporation. Spaulding and Slye LLC. Transactions Granted Early Termination—12/08/2005 U.S. Bancorp ..................................... Wachovia Corporation ....................... 20060277 ......................... 20060279 ......................... wwhite on PROD1PC65 with NOTICES 20060256 ......................... Avnet, Inc. ......................................... General Atlantic Partners 82, L.P. .... Calence, LLC ..................................... NYMEX Holdings, Inc. ....................... Delaware Trust Company, National Association, Wachovia Bank and Trust Company (Cayman) Ltd., Wachovia Bank, National Association, Wachovia Bank of Delaware, National Association, Wachovia Trust Company of California. Calence, LLC. NYMEX Holdings, Inc. Transactions Granted Early Termination—12/09/2005 20060253 20060254 20060282 20060285 ......................... ......................... ......................... ......................... VerDate Aug<31>2005 Goense Bounds & Partners A, L.P. .. Goense Bounds & Partners A, L.P. .. Aetna Inc. .......................................... Merrill Corporation ............................. 16:09 Jan 09, 2006 Jkt 208001 PO 00000 Frm 00035 Frank Scardino .................................. James R. Gates and Angela Gates .. Express Scripts, Inc. ......................... WordWave, Inc. ................................. Fmt 4703 Sfmt 4703 E:\FR\FM\10JAN1.SGM Capital Drywall, Inc. Capital Drywall, Inc. Aetna Specialty Pharmacy, LLC. WordWave, Inc. 10JAN1

Agencies

[Federal Register Volume 71, Number 6 (Tuesday, January 10, 2006)]
[Notices]
[Pages 1538-1540]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-100]


-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[EPA-HQ-OPPT-2003-0006; FRL-7746-6]


TSCA Chemical Testing; Receipt of Test Data

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice announces EPA's receipt of test data regarding In 
Vitro Dermal Absorption Rate Testing of Certain Chemicals of Interest 
to the Occupational Safety and Health Administration. Data were 
received on the following chemicals: Biphenyl (CAS No. 92-52-4); tert-
butylcatechol (TBC) (CAS No. 98-29-3); carbon disulfide (CAS No. 75-15-
0); catechol (CAS No. 120-80-9); chlorobenzene (CAS No. 108-90-7); 
cyclohexanol (CAS No. 108-93-0); p-dichlorobenzene (CAS No. 106-46-7); 
dimethylacetamide (DMAc) (CAS No. 127-19-5); ethylene dichloride (CAS 
No. 107-06-2); hydroquinone monomethyl ether (HQMME) (CAS No. 150-76-
5); methyl formate (CAS No. 107-31-3); vinyl toluene (CAS No. 25013-15-
4); and p-xylene (CAS No. 106-42-3). These data were submitted pursuant 
to a test rule issued by EPA under section 4 of the Toxic Substances 
Control Act (TSCA).

FOR FURTHER INFORMATION CONTACT: Colby Lintner, Regulatory Coordinator, 
Environmental Assistance Division (7408M), Office of Pollution 
Prevention and Toxics, Environmental Protection Agency, 1200 
Pennsylvania Ave., NW., Washington, DC 20460-0001; telephone number: 
(202) 554-1404; e-mail address: TSCA-Hotline@epa.gov.

SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this Action Apply to Me?

     This action is directed to the public in general. This action may, 
however, be of interest to those persons who are concerned about data 
on health and/or environmental effects and other characteristics of 
this chemical. Since other entities may also be interested, the Agency 
has not attempted to describe all the specific entities that may be 
affected by this action. If you have any questions regarding the 
applicability of this action to a particular entity, consult the person 
listed under FOR FURTHER INFORMATION CONTACT.

B. How Can I Get Copies of this Document and Other Related Information?

    1. Docket. EPA has established an official public docket for this 
action under docket identification (ID) number

[[Page 1539]]

EPA-HQ-OPPT-2003-0006. The official public docket consists of the 
documents specifically referenced in this action, any public comments 
received, and other information related to this action. Although a part 
of the official docket, the public docket does not include Confidential 
Business Information (CBI) or other information whose disclosure is 
restricted by statute. The official public docket is the collection of 
materials that is available for public viewing at the EPA Docket 
Center, Rm. B102-Reading Room, EPA West, 1301 Constitution Ave., NW., 
Washington, DC. The EPA DocketCenter is open from 8:30 a.m. to 4:30 
p.m., Monday through Friday, excluding legal holidays. The EPA Docket 
Center Reading Room telephone number is (202) 566-1744 and the 
telephone number for the OPPT Docket, which is located in EPA Docket 
Center, is (202) 566-0280.
    2. Electronic access. You may access this Federal Register document 
electronically through the EPA Internet under the ``Federal Register'' 
listings at https://www.epa.gov/fedrgstr/.
    Agency Website: EPADOCKET, EPA's electronic public docket and 
comment system was replaced on November 25, 2005, by an enhanced 
federal-wide electronic docket management and comment system located at 
https://www.regulations.gov/. Follow the on-line instructions.
    An electronic version of the public docket is available through 
EPA's electronic public docket and comment system, EPA Dockets. You may 
use EPA Dockets at https://www.epa.gov/edocket/ to submit or view public 
comments, access the index listing of the contents of the official 
public docket, and to access those documents in the public docket that 
are available electronically. Although not all docket materials may be 
available electronically, you may still access any of the publicly 
available docket materials through the docket facility identified in 
Unit I.B.1. Once in the system, select ``search,'' then key in the 
appropriate docket ID number.

II. Test Data Submissions

     Section 4(d) of TSCA requires EPA to publish a notice in the 
Federal Register reporting the receipt of test data submitted pursuant 
to test rules promulgated under section 4(a) within 15 days after these 
data are received by EPA.
     1. Test data for biphenyl were submitted by the Biphenyl Work 
Group and received by EPA on June 17, 2005. The submission includes a 
final study report submission titled: ``In Vitro Dermal Absorption Rate 
Testing.'' (See document ID No. EPA-HQ-2003-0006-0273.) The submission 
also includes a letter clarifying that the Biphenyl Work Group is not 
claiming trade secrecy or confidentiality on this report.
     2. Test data for TBC were submitted by the Tertiary-Butylcatechol 
Consortium and received by EPA on July 20, 2005. The submission 
includes a final report titled: ``[14C] Tert-Butylcatechol 
(TBC): Percutaneous Penetration of [14C] Tert-Butylcatechol 
Through Human Split-thickness Skin Membranes (in-vitro).'' (See 
document ID No. EPA-HQ-2003-0006-0284.)
     3. Test data for carbon disulfide were submitted by the Carbon 
Disulfide Dermal Absorption Task Group (Task Group) of the American 
Chemistry Council and received by EPA on August 15, 2005. The 
submission includes an appended final study report titled: ``Carbon 
Disulfide: In Vitro Dermal Absorption Rate Testing.'' (See document ID 
No. EPA-HQ-2003-0006-0289.)
     4. Test data on catechol were submitted by the Catechol Consortium 
and received by EPA on August 26, 2005. The submission includes a final 
study report titled ``[14C] Catechol: Percutaneous 
Penetration of [14C] Catechol Through Human Split-thickness 
Skin Membranes (in-vitro).'' (See document ID No. EPA-HQ-2003-0006-
0287.)
     5. Test data for chlorobenzene were submitted by the Chlorobenzene 
Producers Association (CPA) and received by EPA on June 6, 2005. The 
submission includes a final study report titled ``Chlorobenzene: In 
Vitro Dermal Absorption Rate Testing.'' (See document ID No. EPA-HQ-
2003-0006-0255.)
     6. Test data for cyclohexanol were submitted on behalf of the 
Cyclohexanol Dermal Absorption Testing Committee and received by EPA on 
August 29, 2005. The submission includes a final study report from 
SafePharm Laboratories titled: ``The In Vitro Dermal Absorption of 
[14C] Cyclohexanol through Human Skin.'' (See document ID 
No. EPA-HQ-2003-0006-0286.)
     7. Test data for p-dichlorobenzene were submitted by the 
Chlorobenzene Producers Association and received by EPA on June 6, 
2005. The submission includes a final study report titled: ``p-
Dichlorobenzene: In Vitro Dermal Absorption Rate Testing.'' (See 
document ID No. EPA-HQ-2003-0006-0255.)
     8. Test data for DMAc were submitted by DuPont Chemical Solutions 
Enterprise and received by EPA on June 21, 2005. The submission 
includes a final study report titled: ``Dimethylacetamide: In Vitro 
Dermal Absorption Rate Testing.'' (See document ID No. EPA-HQ-2003-
0006-0274.)
     9. Test data for ethylene dichloride were submitted by the 
Hazardous Air Pollutant (HAP) Task Force and received by EPA on June 
24, 2005. The submission includes a final study report titled: 
``Ethylene Dichloride: In Vitro Dermal Absorption Rate Testing.'' (See 
document ID No. EPA-HQ-2003-0006-0280.)
     10. Test data for HQMME were submitted by the Hydroquinone 
Monomethyl Ether Dermal Absorption Task Group (Task Group) of the 
American Chemistry Council Hydroquinone Precursors and Derivatives 
Panel, and received by EPA on September 27, 2005. The submission 
includes an appended final study report titled: ``Hydroquinone 
Monomethyl Ether: Measurement of the In Vitro Rate of Percutaneous 
Absorption Through Human Skin.'' (See document ID No. EPA-HQ-2003-0006-
0293.)
    11. Test data for methyl formate were submitted by Celanese 
Chemicals and received by EPA on July 18, 2005. The submission includes 
a final study report titled: ``Methyl Formate: In Vitro Dermal 
Absorption Rate Testing.'' (See document ID Nos. EPA-HQ-2003-0006-0281 
and EPA-HQ-2003-0006-0282.) The submission also includes a letter 
clarifying that Celanese is not claiming confidentiality on this 
report.
     12. Test data for vinyl toluene were submitted on behalf of 
Deltech Corporation by the University of Louisiana and received by EPA 
on April 4, 2005. The submission includes a final study report 
submission titled: ``Vinyl Toluene: In Vitro Dermal Absorption Rate 
Testing.'' (See document ID Nos. EPA-HQ-2003-0006-0247 and EPA-HQ-2003-
0006-0248.) The submission also includes two letters clarifying that 
the study is not claimed confidential or trade secret.
     13. Test data for p-xylene were submitted by the p-Xylene Dermal 
Absorption Task Group of the American Chemistry Council and received by 
EPA on September 27, 2005. The submission includes an appended final 
study report titled: ``p-Xylene: In Vitro Dermal Absorption Rate 
Testing.'' (See document ID No. EPA-HQ-2003-0006-0291.)
     These chemical substances are used in a wide variety of 
applications as industrial solvents, which may result in exposures of a 
substantial number of workers as described in the support document for 
the Proposed Rule (64 FR

[[Page 1540]]

31074, June 9, 1999, Table 3 - Exposure Information for Chemical 
Substances).
     EPA has initiated its review and evaluation process for these 
submissions. At this time, the Agency is unable to provide any 
determination as to the completeness of the submissions.

    Authority: 15 U.S.C. 2603.

List of Subjects

    Environmental protection, Hazardous substances.


    Dated: December 29, 2005.
Jim Willis,
Director, Chemical Control Division, Office of Pollution Prevention and 
Toxics.

[FR Doc. E6-100 Filed 1-9-06; 8:45 am]
BILLING CODE 6560-50-S
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.